Andere talen Cybin Inc.

Aandelen

CYBN

CA23256X1006

Beurs gesloten - Nyse Andere beurzen 22:00:00 12-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,299 ^USD	-1,42%		-0,33%	-27,07%

11/06	Cybin Inc. Stelt Atul R. Mahableshwarkar aan als Senior Vice President, Klinische Ontwikkeling	CI
06/05	Cybin geeft een bedrijfsupdate over recente klinische prestaties en belangrijke opkomende katalysatoren in zijn ontwikkelingspijplijn	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development	11/06
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development	11/06
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024	29/05
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase	14/05
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones	07/05
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones	06/05
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	06/05
Cybin to Participate at the 27th Annual Milken Institute Global Conference	25/04
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry	18/04
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	17/04
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	16/04
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder	16/04
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	10/04
Cybin : MATERIAL CHANGE REPORT - Form 6-K	22/03
Cybin : AGENCY AGREEMENT - Form 6-K	21/03
Cybin Inc. announced that it has received $150 million in funding from a group of investors	19/03
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas	18/03
Sector Update: Health Care Stocks Softer Friday Afternoon	15/03
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	15/03
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder	15/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cybin Inc.

Aandelen

CYBN

CA23256X1006

Andere talen

Filters